[go: up one dir, main page]

AR055560A1 - Derivados del (1,5-difenil-1h-pirazol-3-il)oxadiazol su preparacion, composicion terapeutica y uso del compuesto para la preparacion de medicamentos - Google Patents

Derivados del (1,5-difenil-1h-pirazol-3-il)oxadiazol su preparacion, composicion terapeutica y uso del compuesto para la preparacion de medicamentos

Info

Publication number
AR055560A1
AR055560A1 ARP060100610A ARP060100610A AR055560A1 AR 055560 A1 AR055560 A1 AR 055560A1 AR P060100610 A ARP060100610 A AR P060100610A AR P060100610 A ARP060100610 A AR P060100610A AR 055560 A1 AR055560 A1 AR 055560A1
Authority
AR
Argentina
Prior art keywords
alkyl
unsubstituted
trifluoromethoxy
alkoxy
atom
Prior art date
Application number
ARP060100610A
Other languages
English (en)
Inventor
Francis Barth
Christian Ccngy
Patrick Gueule
Murielle Rinaldi-Carmona
Broeck Didier Van
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35079215&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR055560(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR055560A1 publication Critical patent/AR055560A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

Se incluye composicion farmacéutica en base al compuesto, preparacion del compuesto de formula (1) y uso del compuesto para preparar medicamentos. Reivindicacion 1: Compuesto que responde a la formula (1) en la que: R1 representa un radical heterocíclico elegido entre los compuestos de formulas (2); R1a representa un alquilo C1-7 no sustituido o sustituido con: a) uno o varios átomos de halogeno; b) alcoxi C1-4, trifluorometoxi o fenoxi; c) fenilo no sustituido o mono- di- o trisustituido con sustituyentes elegidos independientemente entre un átomo de halogeno, alquilo C1-4, alcoxi C1-4, trifluorometilo o trifluorometoxi; d) un radical heterocíclico aromático elegido entre tienilo, pirrolilo, imidazolilo, furilo o pirazolilo; un radical C3-12 carbocíclico no aromático, no sustituido o sustituido una o varias veces con un alquilo C1-4; un fenilo no sustituido o mono-, di- o trisustituido con sustituyentes elegidos independientemente entre un átomo de halogeno, alquilo C1-4, alcoxi C1-4, trifluorometilo, o trifluorometoxi; -NR5R6, -NR7COR8; -COOR9; -CONR10R11; S-R12; -S(O)mR13 en el que m es 1 o 2; -O-R14; R1b representa alquilo c1-7 no sustituido o sustituido con: a) uno o varios átomos de halogeno; b) alcoxi C1-4, trifluorometoxi o fenoxi; c) fenilo no sustituido o mono- di- o trisustituido con sustituyentes elegidos independientemente entre un átomo de halogeno, alquilo C1-4, alcoxi C1-4, trifluorometilo o trifluorometoxi; d) un radical heterocíclico aromático elegido entre tienilo, pirrolilo, imidazolilo, furilo o pirazolilo; un radical C3-12 carbocíclico no aromático, no sustituido o sustituido una o varias veces con un alquilo C1-4; un fenilo no sustituido o mono-, di- o trisustituido con sustituyentes elegidos independientemente entre un átomo de halogeno, alquilo C1-4, alcoxi C1-4, trifluorometilo, o trifluorometoxi; -NR15R16, -NR7COR8; R1c representa: un alquilo C1-7 no sustituido o sustituido con: a) uno o varios átomos de halogeno; b) alcoxi C1-4, trifluorometoxi o fenoxi; c) fenilo no sustituido o mono- di- o trisustituido con sustituyentes elegidos independientemente entre un átomo de halogeno, alquilo C1-4, alcoxi C1-4, trifluorometilo o trifluorometoxi; d) un radical heterocíclico aromático elegido entre tienilo, pirrolilo, imidazolilo, furilo o pirazolilo; un radical C3-12 carbocíclico no aromático, no sustituido o sustituido una o varias veces con un alquilo C1-4; un fenilo no sustituido o mono-, di- o trisustituido con sustituyentes elegidos independientemente entre un átomo de halogeno, alquilo C1-4, alcoxi C1-4, trifluorometilo, o trifluorometoxi; -NR15R16, -NR7COR8; R2 representa alquilo C1-5 o ciano; R3 representa fenilo no sustituido o mono-, di- o trisustituido con sustituyentes elegidos independientemente entre un átomo de halogeno, alquilo C1-4, alcoxi C1-4, trifluorometilo, trifluorometoxi o un grupo S(O)nAlk; R4 representa fenilo no sustituido o mono-, di- o trisustituido con sustituyentes elegidos independientemente entre un átomo de halogeno, alquilo C1-4, alcoxi C1-4, trifluorometilo, trifluorometoxi o un grupo S(O)nAlk; R5 y R6 representan cada uno independientemente un átomo de H o un alquilo C1-4; o bien R5 y R6 junto con el átomo de N al que están unidos constituyen un radical heterocíclico elegido entre azetidina, pirrolidina, piperidina o morfolina; R7 representa un átomo de H o alquilo C1-3; R8 representa alquilo C1-4; R9 representa alquilo C1-4; R10 y R11 representa cada uno independientemente un átomo de H, alquilo C1-4 o bencilo; o bien R10 y R11 junto con el átomo de N al que están unidos constituyen un radical heterocíclico elegido entre azetidina, pirrolidina, piperidina o morfolina; R12 representa un átomo de H alquilo C1-7, cicloalquilo C3-7, cicloalquil C3-7-metilo, bencilo o fenetilo; R13 representa alquilo C1-7, cicloalquilo C3-7, cicloalquil C3-7-metilo, bencilo o fenetilo; R14 representa alquilo C1-7, fenilo no sustituido o mono-, di- o trisustituido con sustituyentes elegidos independientemente entre un átomo de halogeno, alquilo C1-4, alcoxi C1-4, trifluorometilo, o trifluorometoxi; R15 y R16 representan cada uno independientemente un átomo de H o alquilo C1-4; n representa 0, 1 o 2; Alk representa alquilo C1-4, así como sus hidratos o sus solvatos.
ARP060100610A 2005-02-21 2006-02-21 Derivados del (1,5-difenil-1h-pirazol-3-il)oxadiazol su preparacion, composicion terapeutica y uso del compuesto para la preparacion de medicamentos AR055560A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0501860A FR2882365B1 (fr) 2005-02-21 2005-02-21 Derives de 2-(1,5-diphenyl-1h-pyrazol-3-yl)-1,3,4-oxadiazole leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
AR055560A1 true AR055560A1 (es) 2007-08-22

Family

ID=35079215

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100610A AR055560A1 (es) 2005-02-21 2006-02-21 Derivados del (1,5-difenil-1h-pirazol-3-il)oxadiazol su preparacion, composicion terapeutica y uso del compuesto para la preparacion de medicamentos

Country Status (25)

Country Link
US (1) US7632852B2 (es)
EP (1) EP1853595A1 (es)
JP (1) JP4812778B2 (es)
KR (1) KR20070107053A (es)
CN (1) CN101119990A (es)
AR (1) AR055560A1 (es)
AU (1) AU2006215443A1 (es)
BR (1) BRPI0606845A2 (es)
CA (1) CA2597359A1 (es)
DO (1) DOP2006000045A (es)
EA (1) EA200701779A1 (es)
FR (1) FR2882365B1 (es)
GT (1) GT200600082A (es)
IL (1) IL185163A0 (es)
MA (1) MA29261B1 (es)
MX (1) MX2007009994A (es)
NO (1) NO20074763L (es)
NZ (1) NZ560790A (es)
PA (1) PA8663901A1 (es)
PE (1) PE20061038A1 (es)
SV (1) SV2007002422A (es)
TW (1) TW200640916A (es)
UY (1) UY29388A1 (es)
WO (1) WO2006087480A1 (es)
ZA (1) ZA200706953B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
KR101100028B1 (ko) * 2006-09-29 2011-12-29 주식회사 녹십자 칸나비노이드 ｃｂ1 수용체 길항제로서의 헤테로아릴-피라졸 유도체
US7875647B2 (en) 2006-09-29 2011-01-25 Green Cross Corporation Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists
US20080207704A1 (en) * 2007-02-27 2008-08-28 The Green Cross Corporation Heteroaryl-imidazole derivatives as cannabinoid cb1 receptor antagonists
US7705024B2 (en) 2007-04-12 2010-04-27 National Health Research Institutes Oxadiazole compounds
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009078498A1 (en) * 2007-12-17 2009-06-25 Green Cross Corporation Biarylpyrazole 4-carboxamides as cannabinoid cb1 receptor ligands
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
US8309584B2 (en) * 2008-09-25 2012-11-13 Green Cross Corporation Sulfur containing pyrazole-heterocycle derivatives as cannabinoid CB1 receptor antagonists
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
BR112012003973A2 (pt) 2009-08-26 2015-09-08 Sanofi Sa hidratos de fluoroglicosídeo heteroaromático cristalinos, produtos farmacêuticos compreendendo estes compostos e seu uso
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
CN109651350B (zh) * 2019-01-11 2022-05-24 贵州大学 一类杂环取代的1,3,4-噁(噻)二唑类化合物及其制备方法和用途
CN109942567B (zh) * 2019-04-30 2023-04-07 贵州大学 一种1,3,4-噁(噻)二唑基的咪唑类化合物及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09124571A (ja) * 1995-11-01 1997-05-13 Japan Tobacco Inc アミド化合物及びその用途
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
US6825209B2 (en) * 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
EP1556373A1 (en) * 2002-10-18 2005-07-27 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
CA2505945A1 (en) * 2002-12-02 2004-06-17 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives useful as cox-i inhibitors
FR2856683A1 (fr) * 2003-06-25 2004-12-31 Sanofi Synthelabo Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
BRPI0606845A2 (pt) 2009-07-21
WO2006087480A1 (fr) 2006-08-24
JP4812778B2 (ja) 2011-11-09
ZA200706953B (en) 2009-03-25
DOP2006000045A (es) 2006-11-15
US7632852B2 (en) 2009-12-15
MA29261B1 (fr) 2008-02-01
FR2882365A1 (fr) 2006-08-25
JP2008530188A (ja) 2008-08-07
KR20070107053A (ko) 2007-11-06
AU2006215443A1 (en) 2006-08-24
NZ560790A (en) 2009-08-28
MX2007009994A (es) 2007-10-10
TW200640916A (en) 2006-12-01
IL185163A0 (en) 2007-12-03
UY29388A1 (es) 2006-10-02
PA8663901A1 (es) 2006-12-07
NO20074763L (no) 2007-11-16
EP1853595A1 (fr) 2007-11-14
GT200600082A (es) 2006-10-19
PE20061038A1 (es) 2006-11-24
SV2007002422A (es) 2007-01-17
CN101119990A (zh) 2008-02-06
CA2597359A1 (fr) 2006-08-24
FR2882365B1 (fr) 2007-09-07
EA200701779A1 (ru) 2008-02-28
US20080039510A1 (en) 2008-02-14

Similar Documents

Publication Publication Date Title
AR055560A1 (es) Derivados del (1,5-difenil-1h-pirazol-3-il)oxadiazol su preparacion, composicion terapeutica y uso del compuesto para la preparacion de medicamentos
AR041250A1 (es) Derivados de sulfonamida como inhibidores de enzimas convertidoras de tnf-alfa
PE20080830A1 (es) Compuestos derivados de sulfonilo que modulan el receptor cb2
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
AR070992A1 (es) Derivados de 2-aril-6-fenil-inidazo[1,2a]piridinas, su preparacion, composiciones farmaceuticas y su uso en enfermedades que implican los receptores nucleares nurr-1
AR053994A1 (es) Sulfonilpirrolidinas sustituidas procedimiento para su preparacion y su uso como medicamentos
CO6270328A2 (es) Derivados de pirrolo [2,3] pirimidina como inhibidores de proteinas quinasas b
AR068657A1 (es) Derivados de piperidina y piperazina
AR062640A1 (es) Compuestos de azolcarboxamidas y composiciones herbicidas
AR058010A1 (es) Derivados biciclicos como inhibidores de p38 y composicion farmaceutica en base al compuesto
AR054799A1 (es) Derivados de oxindol
AR053171A1 (es) N-hidroxiamidas omega-sustituidos con grupos triciclicos como inhibidores de la histona deacetilasa sus preparaciones y empleo en formulaciones farmaceuticas
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR069796A1 (es) Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen
AR052673A1 (es) Derivados del 1,5-diarilpirrol,su preparacion y su aplicacion en la terapeutica
AR049418A1 (es) Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
AR065863A1 (es) Derivados de imidazolidinona
CO6351693A2 (es) Nuevos derivados de acilamonobenzamida
AR051966A1 (es) Derivados de acido fenoxiacetico utiles para el tratamiento de enfermedades respiratorias
AR060812A1 (es) Moduladores de receptores metabotropicos de glutamato mglur5, composiciones farmaceuticas que los contienen y usos en procesos patofisiologicos y trastornos que afectan el scn
AR056519A1 (es) 4-feniltetrahidroisoquinolinas sustituidas, composiciones farmaceuticas que las contienen y usos terapeuticos en trastornos renales, respiratorios y otros
PE20120657A1 (es) Compuesto para el tratamiento de trastornos metabolicos
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
AR077156A1 (es) Inhibidores de transportador de glicina-1
AR040570A1 (es) Deriados de acilaminotiazol, su preparacion y su aplicacion en terapeutica

Legal Events

Date Code Title Description
FB Suspension of granting procedure